Last $18.35 USD
Change Today +0.29 / 1.61%
Volume 251.9K
THRX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 10:30 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Open
$18.46
Previous Close
$18.06
Day High
$18.62
Day Low
$18.05
52 Week High
07/3/14 - $31.80
52 Week Low
02/2/15 - $10.58
Market Cap
2.1B
Average Volume 10 Days
1.2M
EPS TTM
$-1.13
Shares Outstanding
116.6M
EX-Date
03/10/15
P/E TM
--
Dividend
$1.00
Dividend Yield
2.75%
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

theravance inc (THRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $515.4K
Compensation as of Fiscal Year 2013.

theravance inc (THRX) Key Developments

Theravance, Inc. Announces Cash Dividend, Payable on March 31, 2015

Theravance Inc. announced that the company's Board of Directors has declared a $0.25 per share cash dividend to be paid on March 31, 2015 to stockholders of record as of the close of business on March 12, 2015.

Theravance Inc. Announces Consolidated Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014

Theravance Inc. announced consolidated unaudited financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, total net revenue was $7,280,000 against $1,473,000 a year ago. Income from operations were $130,000 against loss from operations of $7,417,000 a year ago. Loss from continuing operations, net of tax was $15,926,000 or $0.14 basic and diluted per share against $8,894,000 or $0.08 basic and diluted per share a year ago. Net loss was $15,926,000 against $49,929,000 a year ago. Basic and diluted net loss per common share was $0.14 against $0.46 a year ago. Total revenue which primarily resulted from royalties of $10.5 million from net sales of RELVAR(r)/BREO(r) ELLIPTA(r) and ANORO(r) ELLIPTA(r), offset by amortization of intangible assets of approximately $3.5 million. The majority of the royalties for the fourth quarter were driven by BREO sales, which grew 142% versus the third quarter. This was mainly due to growth in the U.S. and in Japan, associated with the ending of the Ryotan restrictions. For the full year, total net revenue was $8,433,000 against $4,532,000 a year ago. Loss from operations were $33,929,000 against $28,795,000 a year ago. Loss from continuing operations, net of tax was $73,530,000 or $0.66 basic and diluted per share against $30,633,000 or $0.30 basic and diluted per share a year ago. Net loss was $168,464,000 against $170,701,000 a year ago. Basic and diluted net loss per common share was $1.50 against $1.67 a year ago.

Theravance Inc. to Report Q4, 2014 Results on Feb 18, 2015

Theravance Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Feb 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $18.35 USD +0.29

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ironwood Pharmaceuticals Inc $15.99 USD +0.54
Nektar Therapeutics $12.72 USD -0.35
Progenics Pharmaceuticals Inc $6.58 USD +0.071
Sucampo Pharmaceuticals Inc $13.28 USD -2.10
Synergy Health PLC 2,138 GBp +8.00
View Industry Companies
 

Industry Analysis

THRX

Industry Average

Valuation THRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 244.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 129.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit www.thrxinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.